ClinicalTrials.gg

Program

sonrotoclax

Also written as “Sonrotoclax”, “BGB-11417” and “Sonrotoclax Tablet”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Multiple Myeloma · Waldenstrom Macroglobulinemia · Leukemia, Myeloid, Acute, led by BeOne Medicines.

Furthest: phase 3, since Oct 3, 202316 company-led studies, 13 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines1613 open or runningphase 3since Oct 3, 2023Feb 18, 2020Nov 2026phase 2 · NCT04973605

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Feb 18, 2020.

  1. Feb 23, 2021Phase 2 study in Leukemia, Myeloid, AcuteNCT04771130 · 260 planned · United States, Australia, China and more
  2. May 7, 2021Phase 1 study in Mature B-cell MalignanciesNCT04883957 · 64 enrolled · China
  3. Jul 7, 2021Phase 2 study in Multiple MyelomaNCT04973605 · 246 planned · United States, Australia, Brazil and more
  4. Jul 21, 20222 phase 2 studiesNCT05471843, NCT05479994
  5. Apr 25, 2023Phase 1 study in Healthy VolunteersNCT05844111 · 6 enrolled · United States
  6. Jul 11, 2023Phase 2 study in Waldenstrom MacroglobulinemiaNCT05952037 · 114 enrolled · United States, Australia, Canada and more
  7. Oct 3, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06073821 · 652 enrolled · United States, Australia, Austria and more
  8. Oct 9, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06637501 · 94 enrolled · United States, Brazil, China and more
  9. Nov 18, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06697184 · 258 planned · United States, Australia, Brazil and more
  10. Dec 16, 2024Phase 3 study in Lymphoma, Mantle-CellNCT06742996 · 300 planned · United States, Argentina, Australia and more
  11. Apr 17, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06943872 · 630 planned · United States, Argentina, Australia and more
  12. Dec 2, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07277231 · 500 planned · United States, Australia, Brazil and more
  13. May 22, 2026Phase 1 study in Healthy VolunteersNCT07628881 · 12 enrolled · Australia
  14. Sep 29, 2026Phase 1 study in Hepatic ImpairmentNCT07855991 · 12 planned

Ahead

  1. Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06637501
  2. Nov 2026Primary completion: phase 2 study in Multiple MyelomaNCT04973605
  3. Feb 8, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07855991
  4. May 31, 2027Primary completion: phase 1 study in Mature B-Cell MalignanciesNCT04277637

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07855991Hepatic Impairment1Not yet recruitingFeb 8, 202712
NCT07628881Healthy Volunteers · Australia1CompletedSep 26, 202612
NCT07277231Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more3RecruitingFeb 2031500
NCT06943872Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3RecruitingSep 30, 2029630
NCT06742996Lymphoma, Mantle-Cell · United States, Argentina, Australia and more3RecruitingAug 31, 2028300
NCT06697184Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more2RecruitingNov 30, 2029258
NCT06637501Leukemia, Lymphocytic, Chronic, B-Cell · United States, Brazil, China and more2Active, not recruitingNov 202694
NCT06073821Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingFeb 2032652
NCT05952037Waldenstrom Macroglobulinemia · United States, Australia, Canada and more2Active, not recruitingSep 22, 2026114
NCT05844111Healthy Volunteers · United States1CompletedJun 18, 20236
NCT05479994Leukemia · China2Active, not recruitingJan 24, 2025100
NCT05471843Lymphoma, Mantle-Cell · United States, Argentina, Belgium and more2Active, not recruitingJul 18, 2025125
NCT04973605Multiple Myeloma · United States, Australia, Brazil and more2RecruitingNov 2026246
NCT04883957Mature B-cell Malignancies · China1CompletedSep 1, 202664
NCT04771130Leukemia, Myeloid, Acute · United States, Australia, China and more2RecruitingAug 31, 2028260
NCT04277637Mature B-Cell Malignancies · United States, Australia, Germany and more1Active, not recruitingMay 31, 2027437

How it is read

Names in the registry

  • “Sonrotoclax”, 11 entries
  • “BGB-11417”, 5 entries
  • “Sonrotoclax Tablet”, 1 entry
  • “[14C]-BGB-11417”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.